Effects of CYP3A inhibitors on the pharmacokinetics of quizartinib, a potent and selective FLT3 inhibitor, and its active metabolite

AIMS: Quizartinib is an oral, highly potent and selective next‐generation FMS‐like tyrosine kinase 3 (FLT3) inhibitor under investigation in patients with FLT3‐internal tandem duplication‐mutated acute myeloid leukaemia. This drug–drug interaction study assessed the pharmacokinetics (PK) of quizarti...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jianke, Kankam, Martin, Trone, Denise, Gammon, Guy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6710528/
https://www.ncbi.nlm.nih.gov/pubmed/31173645
http://dx.doi.org/10.1111/bcp.14022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6710528/
https://www.ncbi.nlm.nih.gov/pubmed/31173645
http://dx.doi.org/10.1111/bcp.14022

Ejemplares similares